home / stock / cldx / cldx quote
Last: | $33.30 |
---|---|
Change Percent: | -0.98% |
Open: | $33.95 |
Close: | $33.30 |
High: | $34.26 |
Low: | $32.91 |
Volume: | 490,434 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$33.3 | $33.95 | $33.3 | $34.26 | $32.91 | 490,434 | 05-31-2024 |
$33.62 | $34.48 | $33.62 | $34.58 | $33.38 | 615,222 | 05-30-2024 |
$34.22 | $34.81 | $34.22 | $34.89 | $33.98 | 465,094 | 05-29-2024 |
$35.38 | $37.39 | $35.38 | $37.67 | $34.62 | 1,056,246 | 05-28-2024 |
$36.92 | $36.35 | $36.92 | $37.15 | $35.86 | 338,442 | 05-27-2024 |
$36.92 | $36.35 | $36.92 | $37.15 | $35.86 | 338,442 | 05-24-2024 |
$36.32 | $38.17 | $36.32 | $38.81 | $35.8 | 565,201 | 05-23-2024 |
$38.1 | $37.75 | $38.1 | $38.27 | $37.3 | 938,552 | 05-22-2024 |
$37.67 | $37.68 | $37.67 | $37.935 | $37.1 | 403,532 | 05-21-2024 |
$37.75 | $38.21 | $37.75 | $38.21 | $37.53 | 504,943 | 05-20-2024 |
$38.21 | $40.1 | $38.21 | $40.22 | $38.11 | 463,536 | 05-17-2024 |
$39.94 | $40.03 | $39.94 | $40.2575 | $39.42 | 950,952 | 05-16-2024 |
$40.17 | $40.97 | $40.17 | $41.55 | $40.06 | 472,678 | 05-15-2024 |
$39.47 | $40.53 | $39.47 | $41.1 | $39.39 | 552,755 | 05-14-2024 |
$40.11 | $40.38 | $40.11 | $40.81 | $39.95 | 372,718 | 05-13-2024 |
$39.92 | $41.6 | $39.92 | $41.97 | $39.5 | 504,888 | 05-10-2024 |
$41.06 | $41.18 | $41.06 | $41.8794 | $41.005 | 445,535 | 05-09-2024 |
$41.21 | $41.92 | $41.21 | $42.56 | $40.72 | 397,280 | 05-08-2024 |
$42.21 | $41.07 | $42.21 | $43.35 | $40.2 | 911,674 | 05-07-2024 |
$41.65 | $42.61 | $41.65 | $43.15 | $41.61 | 547,114 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data further support barzolvolimab clinical benefit to patients with CSU - HAMPTON,...
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that speci...
2024-05-09 23:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...